Publicly funded Immunization Programs in Canada - Routine Schedule for Infants and Children including special programs and catch-up programs (as of March 2013)

Information on immunization programs was collected by the Canadian Nursing Coalition on Immunization (CNCI). PHAC and the CNCI have worked together since July 2004 to develop this tool containing the latest provincial/territorial program information.

**Routine Schedule for Infants and Children**
Province or Territory	DTaP-IPV-Hib	DTaP-IPV	Tdap or Tdap-IPV	HB	MMR	Var	MMR-Var	Men-C	Men-C-A, C, Y, W-135	Pneu- C-13	Inf	HPV	Rot
Legend: DTaP: Diphtheria, Tetanus, Acellular Pertussis HB: Hepatitis B Hib: Haemophilus Influenzae Type b HPV: Human Papillomavirus Inf: Influenza IPV: Inactivated Poliomyelitis Men-C: Meningococcal conjugate MMR: Measles, Mumps, Rubella MMRV: Measles, Mumps, Rubella, and Varicella Pneu-C-13: Pneumococcal conjugate 13 valent PP23 : Pneumococcal polysaccharide 23 valent Rot: Rotavirus Var: Varicella HR: Children at high risk only (Definitions of High Risk for Publicly-funded Vaccines by Province/Territory)
Recommended use: If meningococcal C conjugate vaccine is given to infants < 12 months of age, a booster dose should be given in the second year of life (from 12 to 23 months of age). The early adolescent dose may be given using either meningococcal C conjugate (Men-C) vaccine or quadrivalent conjugate meningococcal vaccine (Men-C-ACYW) depending on the burden of illness from serogroups A, Y and W135 and the age distribution of cases by serogroup in individual Provinces / territories. Updated Invasive Meningococcal Vaccine Conjugate Recommendations can be found at: Update on the Invasive Meningococcal Disease and Meningococcal Vaccine Conjugate Recommendations (PDF Document - 712 Kb - 40 pages) The HPV vaccine is recommended for females (HPV2 or HPV4) and males (HPV4) between 9 and 26 years of age. Update On Human Papillomavirus (HPV) Vaccines
NACI recom- mendation	2, 4, 6, 18 mths	4-6 yrs	14-16 yrs	Infancy (3 doses) OR Pre-teen/ teen (2-3 doses)	12 mths AND 18 mths OR 4-6 yrs OR MMR-Var 2 doses	12-18 mths AND 18 mths OR 4-6 yrs OR MMR-Var 2 doses	12 mths AND 18 mths OR 4-6 yrs	Infancy (1-4 doses)^{Footnote 1} AND Pre-teen (1 dose)^{Footnote 1}	Pre-teen (1 dose)^{Footnote 1}	2, 4, 6, 12-15 mths	6-59 mths (1-2 doses)	9-18 yrs (3 doses at 0, 2, 6 mths)^{Footnote 2}	2, 4, 6 mths
BC	2, 4, 6 (DTaP- HB-IPV-Hib); 18 mths (DTaP-IPV-Hib)	4-6 yrs	Tdap, Gr. 9	2, 4, 6 mths (DTaP- HB-IPV-Hib)	12 mths, 4-6 yrs	12 mths, 4-6 yrs; Catch-up; Gr. 6		2, (4 HR), 12 mths, Gr. 6		2, 4, (6 HR), 12 mths	6-59 mths	Females Gr. 6	2, 4 mths
AB	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	Gr. 5			12 mths, 4-6 yrs	2, 4, 12 mths	Grade 9 (1 dose)	2, 4, (6 HR), 12 mths	≥ 6 mths	Females Gr. 5
SK	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 8	Gr. 6	Catch-up Gr. 6, 8 until Aug 2013	Catch-up Gr. 6 until Aug. 2015	12, 18 mths	12 mths	Gr. 6	2, 4, (6 HR), 12 mths	≥ 6 mths	Females Gr. 6	2, 4 mths
MB	2, 4, 6, 18 mths	4-6 yrs	Tdap, 14-16 yrs	Gr. 4	4-6 yrs		12 mths	12 mths, Gr. 4 until 2017		2, 4, (6 HR), 12 mths	2012-13 ≥ 6 mths	Females Gr. 6; Catch-up ≤ Gr. 10 in 2012-13
ON	2, 4, 6, 18 mths		Tdap-IPV 4-6 yrs, Tdap 14-16 yrs	Gr. 7	12 mths	15 mths	4-6 yrs	12 mths	Gr. 7	2, 4, (6 HR), 12 mths	≥ 6 mths	Females Gr. 8	2, 4 mths
QC	2, 4, 6, 18 mths		Tdap-IPV 4-6 yrs, Tdap 14-16 yrs	Gr. 4	18 mths		12 mths	12 mths; Catch-up < 18 yrs		2, 4, 12 mths	6-23 mths	Females Gr. 4 (2 doses), 3^rd year of high school (1 dose); Catch-up Females < 18 yrs	2, 4 mths
NB	2, 4, 6, 18 mths	4 yrs (DTaP-IPV or Tdap-IPV)	Tdap, Gr. 7	0, 2, 6 mths		One dose children born between 2000 and 2008; Catch-up 2 doses children born in 2009 or later	12, 18 mths	12 mths	Gr. 9	2, 4, 12 mths	6 mths – 18 yrs	Females Gr. 7
NS	2, 4, 6, 18 mths		Tdap-IPV 4-6 yrs, Tdap Gr. 7	Gr. 7			12 mths, 4-6 yrs	12 mths, Gr. 7		2, 4, 12 mths	≥ 6 mths	Females Gr. 7
PE	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	2, 4, 18 mths			12, 18 mths	12 mths	Gr. 9	2, 4, (6 HR), 18 mths	6-59 mths	Females Gr. 6	2, 4 mths
NL	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	Gr. 6	18 mths		12 mths	12 mths	Gr. 4	2, 4, 12 mths	6-59 mths	Females Gr. 6
NT	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	0, 1, 6 mths; Catch-up Gr.9	12, 18 mths, Post secondary students attending schools outside NT	12 mths; Catch-up <5 yrs, Gr.9		2, 12 mths; Catch-up < 5 yrs, Gr. 9	Post secondary students attending schools outside NT	2, 4, 6, 18 mths	≥ 6 mths	Females Gr. 4; Catch-up Gr. 9-12 2009-14
YT	2, 4, 6 (DTaP-HB-IPV-Hib), 18 mths (DTaP-IPV-Hib)	4-6 yrs (DTaP-IPV or Tdap-IPV)	Tdap, Gr. 9	2, 4, 6 mths (DTaP-HB-IPV-Hib); Catch-up ≤ 19 yrs	12 mths, 4-6 yrs	12 mths, 4-6 yrs		2, 12 mths; Catch-up Gr. 6, post-secondary students not previously immunized		2, 4, (6 HR), 12 mths (3 doses)	> 6mths	Females Gr. 6	2, 4 mths
NU	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9 (14-16 yrs)	0, 1, 9 mths	12, 18 mths; Catch-up Gr. 12	15 mths		12 mths; Catch-up Gr. 9 (14-16 yrs)		2, 4, 6, 15 mths, plus PP23 (1 dose) 2-3 yrs	Universal ≥ 6 mths	Females Gr. 6 (≥ 9 yrs)